Skip to main content
. 2022 Nov 14;2022(11):CD001021. doi: 10.1002/14651858.CD001021.pub4

8.3. Analysis.

8.3

Comparison 8: Continuous aztreonam (AZLI)/tobramycin (TIS) versus intermittent tobramycin (TIS), Outcome 3: Need for additional antibiotics for an exacerbation